Allovir’s Corporate Metamorphosis: A New Beginning as Kalaris Therapeutics

The corporate identity of Allovir Inc. has been formally retired. A significant merger transaction with Kalaris Therapeutics, finalized in March 2025, has resulted in the creation of an entirely new corporate entity. This new company operates with a fresh strategic vision, a different corporate name, and a new ticker symbol for its stock listing.

This decisive move to merge came after Allovir encountered substantial operational challenges. The company’s trajectory had been heavily influenced by disappointing outcomes in its clinical trial programs, which precipitated a drastic reduction of its workforce by approximately 95%. The merger agreement, initially announced in November 2024, signaled the conclusive end of Allovir’s journey as an independent business.

Under the terms of the merger, the ownership... Read more...